Blueprint Medicines Corp (BPMC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Sales | 96,116 | 71,957 | 56,566 | 57,570 | 63,287 |
| Cost of Goods | 3,191 | 215 | 4,553 | 3,557 | 4,471 |
| Gross Profit | 92,925 | 71,742 | 52,013 | 54,013 | 58,816 |
| Operating Expenses | 171,939 | 177,066 | 181,546 | 182,551 | 183,494 |
| Operating Income | -78,823 | -105,109 | -128,980 | -127,981 | -124,207 |
| Interest Expense | 5,895 | 0 | 3,808 | 0 | 5,819 |
| Other Income | 174,034 | -5,748 | -728 | -4,622 | 986 |
| Pre-tax Income | 89,316 | -110,857 | -133,516 | -132,603 | -129,040 |
| Income Tax | 180 | 61 | 197 | 190 | 520 |
| Net Income Continuous | 89,136 | -110,918 | -133,713 | -132,793 | -129,560 |
| Net Income | $89,136 | $-110,918 | $-133,713 | $-132,793 | $-129,560 |
| EPS Basic Total Ops | 1.45 | -1.83 | -2.20 | -2.19 | -2.15 |
| EPS Basic Continuous Ops | 1.45 | -1.82 | -2.20 | -2.19 | -2.15 |
| EPS Diluted Total Ops | 1.40 | -1.83 | -2.20 | -2.19 | -2.15 |
| EPS Diluted Continuous Ops | 1.40 | -1.82 | -2.20 | -2.19 | -2.15 |
| EPS Diluted Before Non-Recurring Items | N/A | -1.82 | -2.20 | -2.19 | -2.15 |
| EBITDA(a) | $-79,206 | $-109,517 | $-137,635 | $-122,023 | $-122,903 |